Back to Agenda
Advancing Pediatric Drug Development in Asia through Real-World Evidence and Regulatory Innovation
Session Chair(s)
Yongjing Zhang, PHD
Senior Director, Global Epidemiology
Johnson & Johnson, China
This session will showcase how Real-World Evidence (RWE) supports pediatric drug development in Asian countries, share US and EU perspectives, and highlight innovations in regulatory strategies, policies, and methodologies to enhance regulatory-grade pediatric RWE.
Learning Objective : Demonstrate emerging trends in the use of RWE in regulatory decision-making in Asia, with real examples of leveraging RWE to accelerate pediatric drug development, highlighting innovative approaches and successful outcomes; Discuss challenges and strategies for high-quality pediatric RWE and explore regulatory frameworks for RWE evaluation through innovative cross-organizational collaborations.
Have an account?